Cancer Patient Guide
Ovarian Cancer: Expert Insights for Treatment Decisions
Curated from expert webinars (part of 150+ across all cancer types) hosted by Cancer Patient Lab, a 501(c)(3) nonprofit. Covers BRCA mutations, PARP inhibitors, platinum-based chemotherapy, debulking surgery, CA-125 monitoring, and clinical trials.
Expert Panel
Oncologists and researchers who contributed insights through Cancer Patient Lab webinars
Tony Letai, MD, PhD
Functional precision medicine — testing drugs on cancer cells
Lisa Butterfield
Cancer vaccines and immunotherapy
Ezra Cohen, MD
AI tools in cancer patient-doctor conversations
Lauren Leiman
Liquid biopsy for cancer monitoring
Selin Kurnaz
Finding the right cancer clinical trial
Massive Bio
Matthew Dons
TIL therapy and cellular immunotherapy
Treatment Topics
Key treatment areas covered across our ovarian cancer webinar series
BRCA Mutations & PARP Inhibitors
BRCA1/2 mutations are found in approximately 15-20% of ovarian cancers and are the strongest predictors of PARP inhibitor response. Olaparib, niraparib, and rucaparib have shown dramatic improvements in progression-free survival as maintenance therapy. Even BRCA-wild-type tumors with homologous recombination deficiency (HRD) may benefit from PARP inhibitors combined with bevacizumab.
Platinum-Based Chemotherapy
Carboplatin-paclitaxel remains the standard first-line chemotherapy for ovarian cancer. Response to platinum-based therapy is one of the most important prognostic factors. Platinum-sensitive recurrence (relapse > 6 months after platinum) allows re-treatment with platinum combinations, while platinum-resistant disease requires alternative agents like pegylated liposomal doxorubicin, topotecan, or gemcitabine.
Debulking Surgery
Optimal cytoreductive (debulking) surgery — achieving no visible residual disease — is one of the strongest predictors of survival in ovarian cancer. The debate between primary debulking surgery and neoadjuvant chemotherapy followed by interval debulking depends on tumor burden, patient fitness, and surgical center expertise. An experienced gynecologic oncologist is critical.
CA-125 Monitoring & Liquid Biopsy
CA-125 is the most widely used biomarker for ovarian cancer, though it has limitations — not all ovarian cancers produce it, and non-cancer conditions can elevate it. Liquid biopsy technologies are emerging as complementary monitoring tools, offering broader molecular insight. Understanding when rising CA-125 warrants imaging or treatment changes requires clinical context.
Immunotherapy & Emerging Treatments
While ovarian cancer has been less responsive to checkpoint inhibitors than some other cancers, specific subtypes (high-grade serous with high tumor mutational burden, MSI-H tumors) may benefit. Cancer vaccines, TIL therapy, and antibody-drug conjugates (mirvetuximab soravtansine for FRa-positive tumors) represent emerging options, particularly in clinical trials.
Common Questions from Ovarian Cancer Patients
Answered by Navis AI, informed by expert webinars and medical guidelines
What does BRCA mutation mean for my ovarian cancer treatment?
How do PARP inhibitors work for ovarian cancer?
What is the role of debulking surgery in ovarian cancer?
How should I interpret my CA-125 levels?
What is the difference between platinum-sensitive and platinum-resistant ovarian cancer?
Should I get genetic testing for ovarian cancer?
What are the treatment options for recurrent ovarian cancer?
What clinical trials are available for ovarian cancer?
Testing Services for Ovarian Cancer
Genomic testing, liquid biopsy, and molecular profiling services relevant to ovarian cancer
Myriad HRD
Homologous recombination deficiency testing
Testing
FoundationOne CDx
Comprehensive genomic profiling
Testing
Guardant360
Liquid biopsy for monitoring
Testing
Tempus
Genomic sequencing and AI-driven insights
Testing
Protean BioDiagnostics
Test integration & review
Testing
BostonGene
Tumor portrait report
Testing
Ovarian Cancer Webinars
From Cancer Patient Lab — a 501(c)(3) nonprofit
Liquid Biopsy for Cancer: Monitoring Treatment Response
Lauren Leiman, Jenn Dickey
Functional Precision Medicine: Testing Drugs on Your Cancer Cells
Tony Letai, MD, PhD
How to Find the Right Cancer Clinical Trial
Selin Kurnaz, Massive Bio
Cancer Vaccines: How They Work and Who Can Benefit
Lisa Butterfield
TIL Therapy: Using Your Own Immune Cells to Fight Cancer
Matthew Dons
How AI Tools Are Changing Cancer Patient-Doctor Conversations
Ezra Cohen, MD
Self-Care During Cancer Treatment
Thanos Kosmidis
How to Access Cancer Treatments: Insurance, Clinical Trials
Chris Beardmore
Paying for Cancer Treatments
Nancy Novack, Mike Yancey, Kevin Fordney
Gut Microbiome and Cancer
Michael Liss, MD, PhD
Get Personalized Ovarian Cancer Insights
Upload your pathology report, genomic test, or lab results. Our AI translates them into plain English and matches you to relevant services and clinical trials.
This page is for informational purposes only and does not constitute medical advice. Content is curated from expert webinars hosted by Cancer Patient Lab, a 501(c)(3) nonprofit. Always consult your oncologist for treatment decisions. Meet our team →